Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)

Inclusion Criteria: * Read and sign the written informed consent form (ICF) after the nature of the study has been fully explained. * All subjects of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug. * Male subjects have agreed not to donate sperm from Day -1 through 90 days after the last dose of study drug. Exclusion Criteria: * Pregnant or breastfeeding. * Other clinically significant medical conditions or laboratory abnormalities